长春瑞滨联合顺铂治疗晚期非小细胞肺癌  

Chemotherapy of vinovelbine and cisplatin in advanced non-small-cell lung cancer

作　　者：万会平[1] 罗政[1] 喻建华[1] 汤志谋[1] 喻瑾瑞[1] 勾安伦[1] 

机构地区：[1]江西省人民医院肿瘤科,南昌330006

出　　处：《江西医药》2002年第3期175-176,共2页Jiangxi Medical Journal

摘　　要：目的观察长春瑞滨(NVB)联合顺铂(PDD)治疗晚期非小细胞肺癌的疗效及其毒副反应。方法用NP方案(NVB+PDD)和EP方案(VP-16+PDD)分别治疗晚期非小细胞肺癌40例,每例患者连续化疗2个周期,比较二组患者的近期疗效和毒副反应的差别。结果NP和EP组化疗有效率(CR+PR)分别为37.5%(15/40)和27.5%(11/40),前者明显高于后者(P<0.05)。但病理类型、分期和既往治疗情况对疗效的影响2组间无显著差异(P>0.05)。骨髓抑制为主要的毒副反应,白细胞下降NP组为77.8%(31/40),EP组为62.5%(25/40),均多为轻中度下降,二者无明显差异(P>0.05)。局部静脉炎发生率NP组为45%(18/40),多为轻中度;EP组为10%(4/40),前者显著高于后者(P<0.01)。结论NVB联合PDD是晚期NSCLC的有效化疗方案,其疗效优于EP方案,毒副反应可耐受,可用于晚期NSCLS的一线治疗。Objective To explore the efficacy and toxicity in the treatment of advanced non-small-cell lung cancer (NSCLC)with vinovelbine(NVB)and cisplatin (PDD).Methods All80cases of ad-vanced NSCLC were divided into two groups.One group was treated with NVB and PDD.The other group was treated with VP-16and PDD.Every case had been treated two cycles and the difference of the recent efficacy and toxicity between two groups were explored.Results The response pates (CR and PR)of groups of NP and EP regimen were37.5%(15/40)and27.5%(11/40)respectively.The dif-ference of two groups was singnificant (P<0.05).The effect of two groups on efficacy in the pathological state,clinical stage and previous treatment or un-treatment were not singnificant (P>0.05)because the number of cases was small.The main toxicity was myelosuppresion.Leukopenia occurred in77.8%(31/40)in the group of NP regimen and in62.5%(25/40)in the group of EP regimen.Most of which in two groups were slight and the difference of two groups was not singnificant (P>0.05).Local venous inflammation occurred in45%(18/40)in group of NP regimen and in10%(4/40)in group of EP reg-imen.Most of which also were slight.The rates of group of NP regimen was higher than the other(P<0.01).Conclusion The combination of NVB and PDD is more effective than EP regimen and tolera-ble for advanced NSCLS patient.It may be first -line chemotherapy to advanced NSCLC.

关 键 词：联合治疗 长春瑞滨 顺铂 治疗 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]